Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Notice to Readers Availability of Diphtheria Antitoxin Through an Investigational New Drug Protocol

Although diphtheria is a rare disease in the United States, access to diphtheria antitoxin (DAT) is essential to ensure effective treatment of a case. The previously available supply of U.S.-licensed DAT (Diphtheria Antitoxin, Equine, Connaught Laboratories, Inc., Swiftwater, Pennsylvania) had an expiration date of January 6, 1997, and should no longer be used. No manufacturer has announced an intention to license a DAT product in the United States.

A DAT product (i.e., Diphtheria Antitoxin, Pasteur Merieux, Lyon, France), licensed in Europe and similar to the previously licensed U.S. product, is now available in the United States through an Investigational New Drug (IND) protocol through CDC. This protocol is designed to enable the emergency treatment of patients with suspected diphtheria. Decisions to dispense DAT from U.S. Public Health Service quarantine stations will be made by medical epidemiology staff of CDC's Child Vaccine Preventable Disease Branch, Epidemiology and Surveillance Division, National Immunization Program, in discussion with the treating physician. Physicians treating a case of suspected diphtheria can contact the diphtheria duty officer, telephone (404) 639-8255, 8 a.m. to 4:30 p.m. eastern time, or (404) 639-2889, all other times. All suspected diphtheria cases should also be reported to local and state health departments.





Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.


All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

 
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #